摘要
目的检测ANXA1在食道癌中的表达,并探讨其变化与食道癌发生发展的关系。方法构建含有185例食道癌的组织芯片,利用免疫组化检测ANXA1在食道癌中的表达,统计学分析其表达与临床病理参数之间的关系以及对食道癌患者预后的影响。结果ANXA1在食道癌中的表达率为35.7%(66/185),而癌旁鳞状上皮中均有表达。ANXA1的缺失表达与肿瘤浸润深度、淋巴结转移、疾病分期以及组织学分化高度相关。生存分析表明ANXA1是判断食道癌患者预后的独立指标。结论ANXA1是鳞癌分化的重要指标,其缺失表达在食道癌的发生进展中起了重要作用。ANXA1可用来判断食道癌患者的预后。
Objective To investigated ANXA1 expression and determine its clinical significance in esophageal carcinoma. Methods Tissue microarray blocks containing tumor specimens obtained from 185 patients were constructed. Expression of ANXA1 in these specimens was analyzed using immunohistochemical studies. Results Expression of ANXA1 was observed in 66 cases （35.7%） of 185 primary tumors. Loss of ANXA1 expression was significantly associated with advanced T stages, lymph node metastases, advanced disease stage, and poor histological differentiation. Loss of ANXA1 expression has a significant correlation with poor survival both in tmivariate and multivariate analyses. Conclusion Our results showed ANXA1 expression significantly decreased with the progression of esophageal cancer, suggesting the importance of ANXA1 as a negative biomarker in cancer development and progression. ANXA1 expression may be used to predict patient outcome.
